arrow
N

Nizar M. Tannir

ut md anderson cancer center
H指数:83
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study

Tazemetostat,一种EZH2抑制剂,在携带SWI/SNF突变的实体瘤中的II期篮式研究

2026-03-250
OAAI
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

纳武利尤单抗联合伊匹木单抗诱导肾髓质癌发生超进展:一项II期试验结果及临床前证据

2025-11-250
OAAI
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling

通过整合基因组学和转录组学分析鉴定肾髓质癌的治疗靶点

2025-10-300
OAAI
A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机II期试验,比较仑伐替尼联合依维莫司与卡博替尼在PD-1免疫检查点抑制剂进展后的转移性透明细胞肾细胞癌患者中的疗效(LenCabo)。

2025-10-180
PRE
20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518)

II期临床试验:评估ivonescimab在既往接受过免疫检查点阻断治疗的晚期透明细胞肾细胞癌患者中的疗效(IVORY试验,NCT06940518)。

2025-10-010
OAAI
Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)

针对寡转移性透明细胞肾细胞癌(ccRCC)的靶向转移放疗(MRWS)且不联合系统治疗的Ⅱ期临床试验,并探究循环肿瘤DNA(ctDNA)

2025-10-010
OAAI
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial

寡转移性透明细胞肾细胞癌的转移灶定向放射治疗(无系统性治疗):一项单臂、单中心、II期试验的主要疗效分析

2025-09-040
PRE
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank

开发生物标志物和风险分层方法:国际肾癌研讨会北美2024年思辨研讨会的共识声明

2025-09-010
PRE
Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity

镰状细胞病诱导CD8+ T细胞发生染色质内卷和铁死亡,以抑制抗肿瘤免疫。

Immunity
IF26.3
2025-05-120
OA
TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma

TFE3融合驱动移位性肾细胞癌中的氧化代谢和铁死亡抵抗

2025-03-270
OA
A novel case of glial transdifferentiation in renal medullary carcinoma brain metastasis
2025-01-200
OA
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Nivolumab联合ipilimumab与舒尼替尼用于晚期肾细胞癌的一线治疗: CheckMate 214 III期试验的疗效和安全性的8年随访结果

2024-11-010
OAAI
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy (vol 13, 1970, 2022)
2024-07-040
OAAI
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

在3期CLEAR研究的最终预设生存分析中,晚期肾细胞癌患者对Lenvatinib联合Pembrolizumab的反应特征

2024-07-012
OA
Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco-Nephrology

评估癌症患者的肾小球滤过率: 美国肿瘤学会的声明

2024-06-071
PRE